| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.084 | 0.03 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.03 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.098 | 0.03 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | 0.067 | 0.03 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.39 | 0.03 |
| mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | 0.07 | 0.03 |
| mRNA | selumetinib:BRD-A02303741 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.086 | 0.03 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.03 |
| mRNA | PD318088 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.03 |